debigirl
13 years ago
Hello,
I've been doing some research on this company and it appears to me that they still have rights and own the compound Homspera, which appears to be amazing in it's capabilities. At least 2 Universities (University of Pittsburg and University of Rochester) as well as a UK company (Scancell) are involved with research and development. Scancell is using Homspera with their own compound in development of a cancer vaccine and the results appear to be hugely successful (Link: http://www.scancell.co.uk/Apps/Content/News/?id=191). Additionally, the military has shown interest and has become involved (Link: http://www.biomedreports.com/2010012626267/immuneregen-otcbb-irbs-gaining-attention-for-its-stem-cell-active-compound.html). These are just 2 of the several articles that I have discovered showing the amazing capabilities of this compound: Homspera. I have emailed IRBS, whose email is still active and requested status of the company and the current research status of Homspera. I also called Customer Service for the investment company that we use and have confirmed that IRBS is still "there" and trading shares. Here's what I think is the case: they were given a 5 year $15M grant by NIH (which is a government agency attached to the US Dept of Health and Human Services) for research in 2010 and I believe that because the military became involved they have been supporting the research on Homspera and that IRBS still owns the rights and licensing to the compound, even though according to their report in mid 2011 they may not be a viable concern anymore. According to all reports Homspera is something close to a miracle compound and I don't think the military or government would allow it to go to the wayside. For the same reason, I don't think IRBS is going to let it out of their ownership or control. Hop on in folks and let's get a piece of this potential jackpot while the buy in is so low! We've invested for 10,000 shares!
adamski
14 years ago
ImmuneRegen BioSciences(R) Reports Scancell Collaboration Yielding Positive Results in Cancer Vaccine Studies of Homspera(R)
IR Biosciences Hldgs (BB) (OTCBB:IRBS)
Intraday Stock Chart
Today : Wednesday 8 September 2010
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBS), today announced that treatment with its lead compound, Homspera®, in combination with a DNA vaccine utilizing Scancell's ImmunoBody® technology significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
ImmuneRegen's Homspera has previously been found to improve the efficacy of a melanoma cancer vaccine in mice, resulting in persistent and specific immune responses associated with inhibition of melanoma tumor growth. Additionally, previous studies have demonstrated efficacy of Homspera in enhancing immune responses to infectious disease vaccines, such as influenza. Both applications are being aggressively developed by ImmuneRegen in combination with significant academic and industry partners.
Scancell is developing therapeutic cancer vaccines, and has recently announced the commencement of a Phase I clinical trial utilizing the company's SCIB1 product being developed for the treatment of melanoma. SCIB1 is a novel DNA vaccine being developed using Scancell's patented ImmunoBody® technology. ImmunoBody® vaccines generate the high-avidity T-cells that kill cancer cells, which may overcome the current limitations of most cancer vaccines. SCIB1 is a piece of DNA which codes for a human antibody molecule designed to express a melanoma protein called Tyrosinase-Related Protein 2 (TRP2) plus additional proteins that help direct the engineered antibody to be taken up by dendritic cells of the immune system, so that immune responses will be developed against tumor cells expressing the TRP2 antigen. A unique advantage of Scancell's Immunobody® technology is that a different component of the engineered antibody targets it specifically to dendritic cells, leading to a significant enhancement of the immune response. According to Scancell, this enhanced immune response against TRP2 is expected to lead to the inhibition and regression of both primary and metastatic melanoma tumor growth.
"We are pleased to see we can positively augment immune responses elicited by Scancell's ImmunoBody® vaccines," said Hal Siegel Ph.D., ImmuneRegen's Chief Scientific Officer. "Based on our previous demonstration of enhanced dendritic cell responses to TRP2-encoding DNA vaccine following Homspera exposure, Scancell's ImmunoBody® vaccine technology presents a very desirable developmental opportunity. We are very happy with our ongoing relationship and recognize that ongoing studies could potentially benefit both companies."
"I am pleased with the results achieved by this collaboration to date and look forward to continuing to work with ImmuneRegen as we progress with follow-up studies," commented Professor Lindy Durrant, Chief Executive Officer of Scancell.
TOUCAN
15 years ago
Fred Hutchinson Cancer Research Center Initiates Studies on ImmuneRegen BioSciences' Cancer Therapy Candidate:
Fred Hutchinson Cancer Research Center to Evaluate Homspera(R) in Novel Cancer Therapy Model; Expand on Previous Homspera Findings in the Domain of Cancer Immunotherapy
SCOTTSDALE, AZ--(Marketwire - 02/10/10) - ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTC.BB:IRBS - News), today announced the execution of an agreement with Fred Hutchinson Cancer Research Center to commence studies utilizing ImmuneRegen's Homspera. Under the agreement the Hutchinson Center will perform exploratory studies on Homspera, specifically focusing on the area of cancer immunotherapy. The Center expects to raise approximately $30 million within the next 3-4 years to support immunotherapy research projects and has recently announced a gift of approximately one-third of that amount. Studies at the Hutchinson Center will be performed under the direction of Dr. Cassian Yee , who has successfully used immune cells from patients with melanoma to cause long-term remission in their tumors.
Recent studies have found Homspera to be effective in enhancing the efficacy of a novel cancer vaccine, and previous studies have revealed anti-tumor effects. These experiments taking place at the Hutchinson Center are designed to expand on this previous research, which has identified a critical role for Homspera in directing the immune system towards fighting cancers -- in particular, aggressive cancers where conventional therapies are ineffective. This work will evaluate the effect of Homspera exposure on patients' own cancer-specific cytotoxic T-cell stimulation. While these initial studies will evaluate melanoma immunotherapy this model also has clinical relevance for a wide-range of cancer types.
"We are excited to be pursuing this relationship, which offers ImmuneRegen the opportunity to have Homspera further evaluated in the area of melanoma by a group with enormous proven expertise. Additionally, following successful findings, we would be situated perfectly to leverage our relationship with research and clinical experts at this leading Cancer Research Center who have experience in developing therapies that translate to real world cancer treatments. This could lead to a more rapid developmental path for Homspera as well," said Hal Siegel, Ph.D., ImmuneRegen's Chief Scientific Officer.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC.BB:IRBS - News), is a development-stage biotechnology company focused on the research, development and licensing of Homspera®. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Homspera is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit http://www.immuneregen.com/
LINK:
http://finance.yahoo.com/news/Fred-Hutchinson-Cancer-iw-3611982489.html?x=0&.v=1
TOUCAN
15 years ago
01-27-10 NEWS:
National Cancer Institute Initiates Studies on ImmuneRegen BioSciences' Vaccine Adjuvant Candidate:
NIH to Evaluate Homspera(R) in Novel Anti-HIV Mucosal Vaccine Model; Expand on Previous Homspera Findings
SCOTTSDALE, AZ--(Marketwire - 01/27/10) - ImmuneRegen BioSciences Inc.?, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTC.BB:IRBS - News), today announced the execution of an agreement with the National Institute of Health (NIH) / National Cancer Institute (NCI) to commence studies utilizing ImmuneRegen's Homspera. Under the agreement, the NIH will perform exploratory studies on Homspera relating to mucosal immunity that might lead to subsequent evaluation in models of HIV infection.
Recent studies have found Homspera to be effective in enhancing the efficacy of a novel cancer vaccine, and previous studies have revealed efficacy in the space of infectious disease vaccines, specifically influenza. The studies to be performed at NIH/NCI are designed to expand on that research and further define the mechanisms that make Homspera an effective vaccine adjuvant.
The research will be directed by Jay A. Berzofsky, M.D., Ph.D., Chief of the Vaccine Branch at the Center for Cancer Research within the National Cancer Institute. Dr. Berzofsky has published over 435 scientific publications and has received a number of awards, including the U.S. Public Health Service Superior Service Award. He is the past President of the American Society for Clinical Investigation, and a Fellow of the American Association for the Advancement of Science, and was elected Distinguished Alumnus of the Year for 2007 by the Albert Einstein College of Medicine. He was also elected Chair of the Medical Sciences Section of the American Association for the Advancement of Science (AAAS) 2007-08. He most recently won the NIH Director's Award and NCI Merit Award in 2008.
"We are pleased that Dr. Berzofsky and his team are interested in evaluating the impact of Homspera on mucosal immunity, and hope this is the beginning of a relationship that takes our compound into a number of potential vaccine adjuvant studies," said Hal Siegel, Ph.D., ImmuneRegen's Chief Scientific Officer.
LINK:
http://finance.yahoo.com/news/National-Cancer-Institute-iw-2910826131.html?x=0&.v=1
TOUCAN
15 years ago
01-26-10 NEWS:
IR Biosciences' ImmuneRegen (OTCBB: IRBS) Getting Attention for Its Adult Stem Cell Active Compound
LOS ANGELES, CA--(Marketwire - 01/26/10) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that unlike most newer biotechs of this size and experience in the market, IR Biosciences' ImmuneRegen (OTC.BB:IRBS - News) seems to be gathering quite a bit of attention from places like the NIH, the National Cancer Institute, BARDA (Biomedical Advanced Research and Development Authority), and the armed forces.
ImmuneRegen's development candidate Homspera? appears to be the focus of their attention and it happens to be that the compound has several broad-reaching applications.
Study results have shown its ability to regenerate and strengthen the immune system and enhance wound healing, thereby providing possible treatments for acute radiation exposure, infectious diseases, vaccine adjuvancy, and chemical exposures.
The compound has been modulating the immune system. How it plays a role for various indications has increased the company's confidence in its candidacy for various large market opportunities as well as a rumored and yet to be publicly announced partnership with one integrated pharmaceutical industry player as they get further into clinical studies. That same company has a high level of interest (as do other entities) in purchasing the company's compound as a therapy for cancer -- melanoma specifically.
A complete report on the company with quotes from its CEO Michael Wilhelm is available now at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/26267-immuneregen-otcbb-irbs-gaining-attention-for-its-stem-cell-active-compound-.html
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
LINK:
http://finance.yahoo.com/news/IR-Biosciences-ImmuneRegen-iw-706894884.html?x=0&.v=1
knowledge21
15 years ago
Homspera Treatment Significantly Reduces Growth of Tumors and Improves Survival in Melanoma Study
The study was performed at the University of Pittsburgh under the guidance of Dr. Adriana Larregina, Research Assistant Professor in the departments of Dermatology and Immunology at the University of Pittsburgh School of Medicine. The results of the study showed Homspera augmented a poorly effective vaccine against melanoma, the deadliest form of skin cancer, into a highly effective vaccine. The addition of Homspera as an adjuvant to this vaccine resulted in an increased immune response, significantly (p < 0.01) reducing the size of tumors by approximately 85% after 3 weeks, and increasing the percentage of animals surviving from 0% to 50% after 100 days (the end of the study period). Enhanced immune responses, specifically the cellular immune component, could be critical to the successful prevention and/or treatment of most cancers.
http://www.marketwire.com/press-release/Immuneregen-Biosciences-1090123.html
di4
15 years ago
ImmuneRegen BioSciences Announces IND Submission for Homspera(R) for the Treatment of Idiopathic Pulmonary Fibrosis
May 28, 2009 8:00:00 AM
Email Story Discuss on ZenoBank
View Additional ProfilesPHOENIX, AZ -- (MARKET WIRE) -- 05/28/09 -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is announcing today the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to begin human clinical testing of Homspera, an analog of the endogenous neurokinin Substance P. The company plans to evaluate Homspera initially as a treatment for Idiopathic Pulmonary Fibrosis, a condition for which there are no consistently effective drugs approved for human use in the U.S.
"This marks a major milestone in our efforts to explore the molecular mechanisms and capabilities of Homspera and its potential to treat a range of complications arising from damage to the immune system," commented ImmuneRegen BioSciences CEO Michael K. Wilhelm. "We are encouraged by the results of pre-clinical studies of Homspera and look forward to taking our research to this next important level," he added.
Idiopathic Pulmonary Fibrosis is a progressive interstitial lung disease characterized by scarring of lung tissue. Over time, the formation of scars replaces air sacs with fibrotic tissue, preventing the lung from effectively transferring oxygen into the bloodstream. The disease currently afflicts 5 million people worldwide and kills 40,000 annually, though these numbers are believed to be artificially low due to misdiagnosis (http://www.pulmonaryfibrosis.org/ipf.htm). Recent research suggests Pulmonary Fibrosis is a reaction to microscopic injury to the lung resulting from the inhalation of pollutants, radiation exposure, and other insults.
About Homspera
Homspera is an adult stem cell active compound that has been shown in study results to regenerate and strengthen the immune system and enhance wound healing. Originally identified as providing protection from the lethal effects of acute radiation exposure, Homspera has been shown to affect a number of immunological and non-immunological cell types via its receptor-binding activity at the neurokinin-1 receptor (NK-1R). Studies also demonstrate the compound's hematopoietic stem cell stimulatory activity as well as immunomodulatory and anti-inflammatory activity in a number of model systems. To date, the FDA has issued Pre-Investigational New Drug (PIND) numbers to two derivatives of Homspera: one for Radilex® as a potential treatment of acute radiation exposure, and the other for Viprovex® as a potential treatment for novel forms of influenza.
About ImmuneRegen BioSciences
ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company engaged in the research, development and licensing of the potential drug candidate Homspera and its derivatives Radilex® and Viprovex®. Management is focused on the development of these drug candidates as potential treatments for blood disorders and to accelerate wound healing. Findings to date suggest additional opportunities for these compounds as a vaccine adjuvant and potential treatment for influenza or other microbial ailments, as well as for use as a possible countermeasure for homeland security threats including radiological, chemical and biological agents. For more information, visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-KSB for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
Contact:
John Fermanis
ImmuneRegen BioSciences Inc.
Phone: 480-922-3926
E-mail: Email Contact
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ask ADVFN Intelligence (AI)
Renee
10 years ago
mc67
13 years ago
traderdogzz
15 years ago
cottonmather
15 years ago
Hot Features
Premium
